Medicinski Ogljikov Dioksid Istrabenz Plini (Carbon Dioxide)

Inhaled carbon dioxide raises the partial pressure of CO₂ in arterial blood. Central chemoreceptors in the medulla detect this increase and stimulate the respiratory centers, leading to an elevated respiratory rate and tidal volume, which improves overall ventilation.

The prescribed dose of Medicinski Ogljikov Dioksid Istrabenz Plini is determined by the treating physician based on the patient’s clinical condition, baseline blood gas values, and the intended therapeutic goal. Dosage is individualized and should follow the prescriber’s instructions.

Safety data for carbon dioxide inhalation in pregnancy and lactation are limited. The product should only be used during pregnancy or while breastfeeding if the potential benefit justifies any potential risk to the fetus or infant, and after careful evaluation by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

Unlike pharmacologic agents such as doxapram, carbon dioxide acts physiologically by directly increasing arterial CO₂ levels, which naturally stimulates the respiratory center. This mechanism can provide a rapid, controllable increase in ventilation without the systemic side‑effects associated with some drug‑based stimulants.

Medicinski Ogljikov Dioksid Istrabenz Plini should be stored at ambient temperature, preferably below 25 °C. Keep the gas cylinder upright, protect it from heat sources, direct sunlight, and physical damage. Ensure the cylinder valve is closed when not in use and handle according to local regulations for compressed gases.

The product is administered by inhalation through a calibrated delivery system, such as a ventilator circuit or a specialized gas‑mixing device. Administration is performed by trained healthcare personnel who monitor the patient’s respiratory parameters and adjust the flow rate to achieve the desired therapeutic effect.

The most serious risks include severe hypercapnia leading to respiratory acidosis, acute pulmonary edema, and rare allergic reactions such as anaphylaxis. Continuous monitoring of blood gases and clinical status is essential to detect and manage these potential complications promptly.

Patients with uncontrolled severe COPD exacerbations, acute asthma attacks, or known hypersensitivity to carbon dioxide should not receive this product. Additionally, individuals receiving high‑dose opioid or benzodiazepine therapy should avoid use unless closely monitored by a specialist.